Key result
Autologous cell-seeded tissue-engineered heart valves maintain function with minimal regurgitation and progressive tissue remodeling.
Why the study?
Tissue engineering techniques are being developed to create functional autologous heart valves, but early in vivo evaluation of whole trileaflet tissue-engineered heart valves is needed.
A tissue-engineered heart valve seeded with autologous cells successfully functioned in the pulmonary position of a lamb model for up to 120 days without thrombosis, supporting the feasibility of in vivo tissue-engineered heart valves.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for tissue-engineered valves in lambs; should not yet change clinical practice pending human trials.
Background —Tissue engineering is a new approach in which techniques are being developed to transplant autologous cells onto biodegradable scaffolds to ultimately form new functional autologous tissue. Workers at our laboratory have focused on tissue engineering of heart valves. The present study was designed to evaluate the implantation of a whole trileaflet tissue-engineered heart valve in the pulmonary position in a lamb model. Methods and Results —We constructed a biodegradable and biocompatible trileaflet heart valve scaffold that was fabricated from a porous polyhydroxyalkanoate (pore size 180 to 240 μm; Tepha Inc). Vascular cells were harvested from ovine carotid arteries, expanded in vitro, and seeded onto our heart valve scaffold. With the use of cardiopulmonary bypass, the native pulmonary leaflets were resected, and 2-cm segments of pulmonary artery were replaced by autologous cell–seeded heart valve constructs (n=4). One animal received an acellular valved conduit. No animal received any anticoagulation therapy. Animals were killed at 1, 5, 13, and 17 weeks. Explanted valves were examined histologically with scanning electron microscopy, biochemically, and biomechanically. All animals survived the procedure. The valves showed minimal regurgitation, and valve gradients were <20 mm Hg on echocardiography. The maximum gradient was 10 mm Hg with direct pressures. Macroscopically, the tissue-engineered constructs were covered with tissue, and there was no thrombus formation on any of the specimens. Scanning electron microscopy showed smooth flow surfaces during the follow-up period. Histological examination demonstrated laminated fibrous tissue with predominant glycosaminoglycans as extracellular matrix. 4-Hydroxyproline assays demonstrated an increase in collagen content as a percentage of native pulmonary artery (1 week 45.8%, 17 weeks 116%). DNA assays showed a comparable number of cells in all explanted samples. There was no tissue formation in the acellular control. Conclusions —Tissue-engineered heart valve scaffolds fabricated from polyhydroxyalkanoates can be used for implantation in the pulmonary position with an appropriate function for 120 days in lambs.
No takes yet. Share an insight, caveat, or question.
Sodian et al. (2000) studied Tissue engineering of heart valves (n=5). Autologous cell-seeded tissue-engineered heart valve construct vs. Acellular valved conduit was evaluated on Valve function and tissue formation (echocardiographic, histological, biochemical, biomechanical). Implantation of autologous cell-seeded tissue-engineered heart valves in lambs resulted in functional valves with minimal regurgitation and progressive tissue formation over 120 days.
Synapse has enriched 10 related papers. Consider them for comparative context: